<DOC>
	<DOCNO>NCT00413829</DOCNO>
	<brief_summary>This study evaluation short term effect CNV perfusion same-day administration photodynamic therapy ( PDT ) Visudyne® intravitreal injection Lucentis® ( ranibizumab , 0.3 mg ) . An evaluation short term effect CNV perfusion combine treatment need well understanding treatment effect .</brief_summary>
	<brief_title>Immediate Effects Lucentis® Conjunction With Photodynamic Therapy With Visudyne® Exudative AMD ( IECOMB )</brief_title>
	<detailed_description>The primary objective quantify short term effect CNV perfusion same-day administration photodynamic therapy Visudyne® intravitreal injection ranibizumab . These short term effect assess visual acuity measurement ophthalmic examination include indocyanine green ( ICG ) fluorescein angiography ( FA ) well Optical Coherence Tomography ( OCT ) measurement . The primary variable assessment incidence CNV closure one week combine therapy assess high speed ICG angiography . Fluorescein ICG angiography perform use scan laser ophthalmoscope ( HRA ) . All angiographic study OCT examination evaluate Bern Photographic Reading Center mask fashion . Visual acuity assessment perform Early Treatment Diabetic Retinopathy Study ( ETDRS ) -like visual acuity test chart . A secondary objective explore effect same-day administration photodynamic therapy Visudyne® intravitreal injection ranibizumab : - retinal thickness measure OCT time - change total lesion area , area CNV assess FA - mean change VA baseline time</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Patients 50 year age great Patients subfoveal choroidal neovascularization lesion secondary AMD , either predominantly classic , occult , minimally classic . CNV lesion study eye ≤5400 micron great linear dimension Patients best correct visual acuity ( BCVA ) score 73 24 letter , inclusively , study eye use ETDRSlike grade chart ( approximately 20/40 20/320 ) measure 4 meter Willing return follow schedule visit 6 month period Only one eye assess study . If eye eligible , one bad visual acuity select treatment study unless , base medical reason , investigator deems eye appropriate candidate treatment study Patients BCVA &lt; 33 letter ( approximately 20/200 ) eye Prior treatment study eye verteporfin , externalbeam radiation therapy , vitrectomy , submacular surgery , surgical intervention AMD , transpupillary thermotherapy Previous current intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection device implantation ) study eye Focal laser photocoagulation ( juxta , extra subfoveal ) study eye Concomitant use chronic NSAIDs steroid ( route ) duration study participation ( chronic use define multiple dos take daily three consecutive day time study ) . Note ASA ( aspirin ) take `` low dose '' 100 mg daily ( qd ) prophylaxis myocardial infarction ( MI ) and/or stroke permit study Current use likely need systemic medication know toxic lens , retina optic nerve , include Deferoxamine , Chloroquine/ hydroxychloroquine ( Plaquenil ) , Tamoxifen , Phenothiazines Ethambutol exclude History glaucoma filtration surgery , corneal transplant surgery extracapsular extraction cataract phacoemulsification within six month precede Day One , history postoperative complication within last 12 month precede Day One study eye ( uveitis , cyclitis etc . ) History uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment topical antiglaucomatous medication ) . Aphakia absence posterior capsule study eye Previous violation posterior capsule study eye also exclude unless occur result YAG posterior capsulotomy association prior , posterior chamber intraocular lens implantation Spherical equivalent refractive error study eye demonstrate 8 diopter myopia Presence retinal pigment epithelial tear involve macula study eye Angioid streak precursor CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Active intraocular inflammation ( grade trace ) study eye Any active infection involve eyeball adnexa Vitreous hemorrhage history rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>age relate macular degeneration</keyword>
	<keyword>anti-VEGF therapy</keyword>
</DOC>